IP Library Patent Application 14960692
Patent Application
App. No. 14/960,692

COMPOSITIONS AND METHODS TO INHIBIT KIDNEY STONE GROWTH

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/960,692
Abstract

An oral dosage form or plurality of oral dosage forms comprising as active ingredients citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.

Claims (61)

1 . An oral dosage form or a plurality of dosage forms comprising as active ingredients citric acid, magnesium citrate, phytin, pyridoxine, and musa.

2 . The oral dosage form or plurality of dosage forms of claim 1 , wherein citric acid is present in an amount selected from about 101 mg to about 352 mg, about 101 mg to about 176 mg, about 176 mg to about 700 mg, and about 352 mg to about 700 mg.

3 . The oral dosage form or plurality of dosage forms of claim 1 , wherein magnesium citrate is present in an amount selected from about 76 mg to about 201 mg, about 76 mg to about 150 mg, about 150 to about 226 mg, and about 201 mg to about 225 mg.

4 . The oral dosage form or plurality of dosage forms of claim 1 , wherein phytin is present in an amount selected from about 3 mg to about 400 mg, about 3 mg to about 202 mg, about 3 mg to about 100 mg, about 100 mg to about 600 mg, about 200 mg to about 600 mg, and about 400 mg to about 600 mg.

5 . The oral dosage form or plurality of dosage forms of claim 1 , wherein pyridoxine is present in an amount selected from about 0.2 mg to about 10 mg, about 0.2 mg to about 6 mg, about 0.2 mg to about 2.7 mg, about 2.7 mg to about 15 mg, about 6.0 mg to about 15 mg, and about 10 mg to about 15 mg.

6 . The oral dosage form or plurality of dosage forms of claim 1 , wherein musa is present in amount selected from about 1 mg to about 167 mg, about 1 mg to about 85 mg, about 1 mg to about 41 mg, about 41 mg to about 251 mg, about 85 mg to about 251 mg, and about 167 mg to about 251 mg.

7 . The oral dosage form or plurality of dosage forms of claim 1 , wherein the amount of one of the active ingredients is selected from:

citric acid is present in an amount of about 101 mg to about 700 mg;

magnesium citrate is present in an amount of about 76 mg to about 226 mg;

phytin is present in an amount of about 3 mg to about 600 mg;

pyridoxine is present in an amount of about 0.1 mg to about 15 mg; and

musa is present in amount of about 1 mg to about 251 mg.

8 . The oral dosage form or plurality of dosage forms of claim 1 , wherein the amounts of two of the active ingredients are selected from:

citric acid is present in an amount of about 101 mg to about 700 mg;

magnesium citrate is present in an amount of about 76 mg to about 226 mg;

phytin is present in an amount of about 3 mg to about 600 mg;

pyridoxine is present in an amount of about 0.1 mg to about 15 mg; and

musa is present in amount of about 1 mg to about 251 mg.

9 . The oral dosage form or plurality of dosage forms of claim 1 , wherein the amounts of 3 of the ingredients are selected from:

citric acid is present in an amount of about 101 mg to about 700 mg;

magnesium citrate is present in an amount of about 76 mg to about 226 mg;

phytin is present in an amount of about 3 mg to about 600 mg;

pyridoxine is present in an amount of about 0.1 mg to about 15 mg; and

musa is present in amount of about 1 mg to about 251 mg.

10 . The oral dosage form or plurality of dosage forms of claim 1 , wherein the amounts of 4 of the ingredients are selected from:

citric acid is present in an amount of about 101 mg to about 700 mg;

magnesium citrate is present in an amount of about 76 mg to about 226 mg;

phytin is present in an amount of about 3 mg to about 600 mg;

pyridoxine is present in an amount of about 0.1 mg to about 15 mg; and

musa is present in amount of about 1 mg to about 251 mg.

11 . The oral dosage form or plurality of dosage forms of claim 1 , wherein

citric acid is present in an amount of about 350 mg;

magnesium citrate is present in an amount of about 150 mg;

phytin is present in an amount of about 200 mg;

pyridoxine is present in an amount of about 5 mg; and

musa is present in amount of about 250 mg.

12 . The oral dosage form or a plurality of dosage forms according to claim 1 , wherein the percent inhibition of calcium oxalate crystal formation by the combination of active ingredients is greater than about 92%.

13 . The oral dosage form or plurality of dosage forms according to claim 12 , where the percent inhibition is greater than about 96%.

14 . The oral dosage form or plurality of dosage forms according to claim 12 where the percent inhibition is greater than about 99%.

15 . The oral dosage form or plurality of dosage forms according to claim 1 , comprising an oral dosage form in the form of a capsule.

16 . A method of treating or inhibiting formation of kidney stones comprising administering to a patient in need thereof the oral dosage form or plurality of dosage forms according to claim 1 .

17 . The method of claim 16 , wherein the oral dosage form or plurality of dosage forms comprises

about 101 mg to about 700 mg citric acid;

about 76 mg to about 226 mg magnesium citrate;

about 3 mg to about 600 mg phytin;

about 0.1 mg to about 15 mg pyridoxine; and

about 1 mg to about 251 mg musa.

18 . A method of inhibiting growth of calcium oxalate crystals comprising

contacting an aqueous solution comprising calcium oxalate with the oral dosage form or plurality of dosage forms according to claim 1 .

19 . The method of claim 18 , wherein the oral dosage form or plurality of dosage forms comprises

about 101 mg to about 700 mg citric acid;

about 76 mg to about 226 mg magnesium citrate;

about 3 mg to about 600 mg phytin;

about 0.1 mg to about 15 mg pyridoxine; and

about 1 mg to about 251 mg musa.

20 . The method of claim 19 , wherein

citric acid is present in an amount selected from: about 51 101 mg to about 352 mg, about 101 mg to about 176 mg, about 176 mg to about 700 mg, and about 352 mg to about 700 mg;

magnesium citrate is present in an amount selected from: about 76 mg to about 201 mg, about 76 mg to about 150 mg, about 150 to about 226 mg, and about 201 mg to about 225 mg;

phytin is present in an amount selected from: about 3 mg to about 400 mg, about 3 mg to about 202 mg, about 3 mg to about 100 mg, about 100 mg to about 600 mg, about 200 mg to about 600 mg, and about 400 mg to about 600 mg;

pyridoxine is present in an amount selected from: about 0.2 mg to about 10 mg, about 0.2 mg to about 6 mg, about 0.2 mg to about 2.7 mg, about 2.7 mg to about 15 mg, about 6.0 mg to about 15 mg, and about 10 mg to about 15 mg; and

musa is present in an amount selected from: about 1 mg to about 167 mg, about 1 mg to about 85 mg, about 1 mg to about 41 mg, about 41 mg to about 251 mg, about 85 mg to about 251 mg, and about 167 mg to about 251 mg.

Assignments (2)
CHANGE OF NAME Recorded Apr 13, 2017
From: KIDNEY STONE LABORATORIES, INC
To: KIDNEY STONE RESEARCH COMPANY, INC.
Reel/Frame 042246/0060 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2015
From: HAYER, GREGORY K.; MAGRAB, BRENDAN; WOLFE, HENRY R., JR.
To: KIDNEY STONE LABORATORIES, INC.
Reel/Frame 037223/0522 →